Citi initiates coverage of Gilead Sciences and Vertex Pharmaceuticals at buy in the large U.S. biotech sector. Read more here.

Any new HIV prevention method is not meant to sit on the shelf but to be used by the people who need it to protect themselves ...

Citigroupa expanded its biotech coverage on Wednesday, adding five more stocks to the roster including Amgen (NASDAQ:AMGN), ...

(Howard Dean, 11/13) Miami Herald: CDC Numbers Offer Good News On HIV Infections Overall But Reveal A Crisis For Latinos When the Centers for Disease Control and Prevention published data in May of ...

Researchers have created a groundbreaking antibody that combines targeting, delivery, and immune activation to treat cancer, ...

Researchers have identified a new target to treat atherosclerosis, a condition where plaque clogs arteries and causes major cardiac issues, including stroke and heart attack.

But Dr. Joseph McGowan, HIV services medical director at Northwell Health, said he hadn’t seen a noticeable decline in STI ...

Depending on the subtype, some patients with stage 3 disease can have an "excellent prognosis," Strauss said, with recent ...

Gilead (GILD) reported positive results from a pivotal Phase 3 study of its twice-yearly HIV prevention treatment lenacapavir ...

We need to diversify our HIV workforce with new roles that align with the health and well-being ... scientist with clinical ...

The U.S. syphilis epidemic slowed dramatically last year, gonorrhea cases fell and chlamydia cases remained below prepandemic levels.

From Bettina Bauer, Vice President, US HIV Treatment and Prevention, Gilead Sciences In 2022, there were up to 1.2 million ...